Central Retinal Artery Occlusion: Local Intra-arterial Fibrinolysis versus Conservative Treatment, a Multicenter Randomized Trial

医学 视网膜中央动脉阻塞 随机对照试验 视力 眼科 纤溶 不利影响 外科 内科学
作者
Martin Schumacher,Nicole Eter,Bernhard Jurklies,Christine Gall,Isabel Wanke,Claudia Schmoor,H. Maier-Lenz,L. Solymosi,Hartmut Brueckmann,Aljoscha S. Neubauer,Armin Wolf,Nicolas Feltgen
出处
期刊:Ophthalmology [Elsevier BV]
卷期号:117 (7): 1367-1375.e1 被引量:281
标识
DOI:10.1016/j.ophtha.2010.03.061
摘要

Purpose The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Design Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Participants Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Methods Patients (age 18–75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) <0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. Main Outcome Measures The primary end point was BCVA after 1 month; the secondary end point was safety. Results The mean interval between first symptoms and therapy was 10.99±5.49 hours (CST) and 12.78±5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: −0.44 [standard deviation 0.55]; LIF: −0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (≥0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. Conclusions In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Patients (age 18–75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) <0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. The primary end point was BCVA after 1 month; the secondary end point was safety. The mean interval between first symptoms and therapy was 10.99±5.49 hours (CST) and 12.78±5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: −0.44 [standard deviation 0.55]; LIF: −0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (≥0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
仿生人发布了新的文献求助10
刚刚
刚刚
夏侯剑封完成签到,获得积分10
刚刚
莫默完成签到,获得积分10
1秒前
细腻亦巧发布了新的文献求助50
1秒前
2秒前
2秒前
安静人发布了新的文献求助10
3秒前
碧蓝世界完成签到 ,获得积分10
3秒前
3秒前
ee发布了新的文献求助10
4秒前
英俊的晟睿完成签到,获得积分10
4秒前
4秒前
豆子应助稳重向南采纳,获得20
5秒前
可爱电源完成签到 ,获得积分10
5秒前
5秒前
wangbq完成签到 ,获得积分10
6秒前
6秒前
崔家泽熙完成签到,获得积分10
6秒前
风趣的老太应助细心元枫采纳,获得10
7秒前
CodeCraft应助苏灿采纳,获得10
7秒前
7秒前
赘婿应助Tal采纳,获得50
8秒前
大个应助慕慕倾采纳,获得10
9秒前
9秒前
李健应助Mhl采纳,获得10
9秒前
znn发布了新的文献求助10
9秒前
顾矜应助刘浩采纳,获得10
9秒前
10秒前
zhang-leo发布了新的文献求助10
11秒前
hucaicai完成签到,获得积分10
11秒前
清爽的醉香完成签到 ,获得积分10
11秒前
鱼瓜瓜完成签到,获得积分10
12秒前
12秒前
12秒前
raincloud关注了科研通微信公众号
12秒前
CodeCraft应助小太阳采纳,获得10
13秒前
Lucas应助阳佟半仙采纳,获得10
13秒前
xiaojiu发布了新的文献求助30
13秒前
zhixiang应助kik采纳,获得10
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974797
求助须知:如何正确求助?哪些是违规求助? 3519250
关于积分的说明 11197623
捐赠科研通 3255405
什么是DOI,文献DOI怎么找? 1797769
邀请新用户注册赠送积分活动 877156
科研通“疑难数据库(出版商)”最低求助积分说明 806202